Tara Lin is an Oncology physician affiliated with University of Kansas. OpenAlex indexes 381 publications with 7,291 citations (h-index 32); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3901 Rainbow Blvd
Kansas City, KS 661608500
Telephone
913-588-6030Registry record last updated 8 May 2014.
Clinical trials
- Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
Sponsor: Tara Lin
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year202513 payments
- Janssen Scientific Affairs, LLCProgram year20254 payments
- Daiichi Sankyo Inc.Program year20249 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
65.6%BCL-2 Inhibitor65.6%Venclexta100%Part D≥11 patientsAnti-infectives
34.4%Fluoroquinolone Antibacterial34.4%Levofloxacin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2012–2025 per NIH RePORTER. The latest:
- Expanding access and enrollment to precision medicine trials in Acute Myeloid Leukemia
University of Kansas Medical Center
FY2025$135,949R50CA293244
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML
Journal of Clinical Oncology
2025 - Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Simari, MD
University of Kansas
Diane Cibrik, MD
University of Kansas
Martin Mainster, MD
University of Kansas
Jules Nazzaro, MD
University of Kansas
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”